Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01680458` - Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication

NCT number	NCT03471988
Study type	Interventional
Source	Asahi Kasei Pharma Corporation
Contact
Status	Completed
Phase	Phase 3
Start date	April 16, 2018
Completion date	April 21, 2021

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms